Literature DB >> 19482627

Development of recombinant allergens for diagnosis and therapy.

Matthias Egger1, Michael Hauser, Martin Himly, Nicole Wopfner, Michael Wallner, Fatima Ferreira.   

Abstract

Allergic disease represents an increasing problem in industrialized countries. However, allergy diagnosis and specific immunotherapy, the only curative approach towards the treatment of IgE-mediated disorders, are still performed like in their very beginnings more than a century ago. The use of allergen extracts of undefined contents bears the risk of anaphylactic side effects and sensitization to new allergens during immunotherapy. This review focuses on production, physicochemical, and immunological requirements, as well as on the multiple advantages of recombinant allergens and hypoallergens in comparison to conventional allergen extracts used in allergy diagnosis and therapy. Recombinant allergens offer the perspective of molecule-based allergy diagnosis and consequently safe and patient-tailored immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482627     DOI: 10.2741/E9

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  5 in total

1.  Panallergens and their impact on the allergic patient.

Authors:  Michael Hauser; Anargyros Roulias; Fátima Ferreira; Matthias Egger
Journal:  Allergy Asthma Clin Immunol       Date:  2010-01-18       Impact factor: 3.406

2.  Reshaping the Bet v 1 fold modulates T(H) polarization.

Authors:  Michael Wallner; Michael Hauser; Martin Himly; Nadja Zaborsky; Sonja Mutschlechner; Andrea Harrer; Claudia Asam; Ulrike Pichler; Ronald van Ree; Peter Briza; Josef Thalhamer; Barbara Bohle; Gernot Achatz; Fatima Ferreira
Journal:  J Allergy Clin Immunol       Date:  2011-03-21       Impact factor: 10.793

3.  Display of wasp venom allergens on the cell surface of Saccharomyces cerevisiae.

Authors:  Irina Borodina; Bettina M Jensen; Ib Søndergaard; Lars K Poulsen
Journal:  Microb Cell Fact       Date:  2010-09-24       Impact factor: 5.328

4.  Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome.

Authors:  Matthias Egger; Alexander Jürets; Michael Wallner; Peter Briza; Silke Ruzek; Stefan Hainzl; Ulrike Pichler; Claudia Kitzmüller; Barbara Bohle; Christian G Huber; Fátima Ferreira
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

Review 5.  How relevant is panallergen sensitization in the development of allergies?

Authors:  Olivia E McKenna; Claudia Asam; Galber R Araujo; Anargyros Roulias; Luiz R Goulart; Fatima Ferreira
Journal:  Pediatr Allergy Immunol       Date:  2016-09       Impact factor: 6.377

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.